Tinos Therapeutics, Inc.
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.3Mattributed |
|---|---|
| Latest round | Funding round, $2.3M, 2025-09-04attributed |
| Founded | 2023 |
| Headquarters | CAMBRIDGE, MA |
| Industry | biotechnology |
| Stage | unknown |
| Website | tinostherapeutics.com |
Tinos Therapeutics is a clinical-stage biotech developing oral small-molecule drugs for solid-tumor oncology. It serves cancer patients and pharma partners pursuing kinase-targeted therapies for resistant cancers. Its lead compound targets a kinase undruggable by previously approved agents, an opening big-pharma kinase programs have largely written off.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-09-04 | Funding round | $2.3M | undisclosed |
Detected tech stack
Afterpay, Squarespace, Squarespace Commerce, moment 0, lodash ., React
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $2.3M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $2.3M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | tinostherapeutics.com, read 2026-05-08 |
| Description | self-reported | tinostherapeutics.com, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $2.3M, 2025-09-04 → Funding round, $2.3M, 2025-09-04, sec-edgar, No document URL on file | Latest round | seed, $2.3M, 2025-09-04 → Funding round, $2.3M, 2025-09-04 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes